FORUS Therapeutics is thrilled to announce Weihao Tang as Senior Product Manager. Weihao brings more than 10 years of experience across the pharmaceutical and clinical diagnostics industries, combining a strong scientific foundation with broad commercial expertise....

FORUS Therapeutics is thrilled to announce Marie-Eve Caron as Associate Director, Sales. Marie-Eve brings more than 20 years of pharmaceutical experience, including over 13 years in specialty care across immunology and hematology/oncology. Throughout her career, she...

(OAKVILLE, Ontario) July 6, 2026 ­– FORUS Therapeutics Inc (“FORUS”), a wholly owned subsidiary of PharmaEssentia Corp, is pleased to announce that it has received a Notice of Compliance (NOC) authorizing BESREMI® (ropeginterferon alfa-2b) for the treatment of adults...